double blind study versus placebo and celecoxib osteoarthritis of the knee: a 13 week, randomised, Lumiracoxib is effective in the treatment of

[1]  C. Rordorf,et al.  Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[2]  C. Hawkey,et al.  Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  C. Rordorf,et al.  Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen: a pilot endoscopic study in healthy male subjects , 2003, Alimentary pharmacology & therapeutics.

[4]  P Tugwell,et al.  Prevention of NSAID-induced gastroduodenal ulcers. , 2002, The Cochrane database of systematic reviews.

[5]  J. Deeks,et al.  Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials , 2002, BMJ : British Medical Journal.

[6]  Peter Jüni,et al.  Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? , 2002, BMJ : British Medical Journal.

[7]  R. Moore.  The hidden costs of arthritis treatment and the cost of new therapy--the burden of non-steroidal anti-inflammatory drug gastropathy. , 2002, Rheumatology.

[8]  R. Moskowitz.  The role of anti-inflammatory drugs in the treatment of osteoarthritis: a United States viewpoint. , 2001, Clinical and experimental rheumatology.

[9]  M. Dougados.  The role of anti-inflammatory drugs in the treatment of osteoarthritis: a European viewpoint. , 2001, Clinical and experimental rheumatology.

[10]  G. FitzGerald,et al.  The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.

[11]  S. Hernández-Díaz,et al.  Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. , 2001, The American journal of medicine.

[12]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[13]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.

[14]  F. Silverstein,et al.  Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor , 2000, American Journal of Gastroenterology.

[15]  P. Isakson,et al.  Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. , 1999, Mayo Clinic proceedings.

[16]  L. Laine,et al.  A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. , 1999, Gastroenterology.

[17]  P. Lipsky,et al.  Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. , 1998, Arthritis and rheumatism.

[18]  C. Goldsmith,et al.  Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. , 1988, The Journal of rheumatology.

[19]  H. Paulus.  FDA arthritis advisory committee meeting: serious gastrointestinal toxicity of nonsteroidal antiinflammatory drugs; drug-containing renal and biliary stones; diclofenac and carprofen approved , 1988 .

[20]  R. Moskowitz,et al.  Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. , 1986, Arthritis and rheumatism.

[21]  C. Reynolds,et al.  Pharmacokinetics of Lumiracoxib in Plasma and Synovial Fluid , 2004, Clinical pharmacokinetics.

[22]  H. Wendt,et al.  Celecoxib versus diclofenac in the management of osteoarthritis of the knee. , 2001, Scandinavian journal of rheumatology.

[23]  Thomas J. Schnitzer,et al.  Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update , 2000 .

[24]  J. Vane,et al.  Mechanism of action of antiinflammatory drugs. , 1998, International journal of tissue reactions.